R
River Vision
Developed a biologic to treat the orphan eye disorder Graves Orbitopathy, a very debilitating condition that ultimately can lead to blindness
At a glance
- Status
- Acquired
- Founded
- 2011
- Headquarters
- New York City, United States
- Open positions
- None listed
- Dealroom signal
- 0.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Lead Generation, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2017 | $145M | $145M | Horizon Therapeutics | — |
| SERIES A✓Equity / VC | Dec 2012 | $17M | $68M | Lundbeckfonden Ventures · SR One | — |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Lundbeckfonden Ventures
SR One
Other known investors2 additional known investors
Horizon Therapeutics
Lundbeckfonden
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about River Vision on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See River Vision’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.